Thrombosis Risk Assessment and Clinical Presentation of Covid-19 Pneumonia
Covid-19
Thrombosis Risk Assessment May Predict Clinical Presentation and Length of Hospital Stay in Covid-19 Pneumonia
1 other identifier
observational
70
1 country
1
Brief Summary
Covid-19 mainly affects the respiratory system. Multiple organ dysfunction and a particularly progressive respiratory insufficiency along with a widespread coagulopathy presumed to be due to infection-associated inflammation and the resulting cytokine storm, are strongly associated with high mortality rates. In this study, the association between thrombosis risk and clinical presentation of Covid-19 is investigated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jun 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 5, 2020
CompletedStudy Start
First participant enrolled
June 8, 2020
CompletedFirst Posted
Study publicly available on registry
June 9, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 15, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
July 20, 2020
CompletedSeptember 23, 2020
September 1, 2020
1 month
June 5, 2020
September 21, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
length of hospital stay
from admission to discharge expressed in days
2 months
Study Arms (1)
patients with covid-19 pneumonia
patients with covid-19 pneumonia above 18 years old who were diagnosed by pcr testing and computed tomography of thorax
Eligibility Criteria
Patients with COVID - 19 pneumonia diagnosed in the emergency, internal medicine and cardiology outpatient clinics will be included
You may qualify if:
- patients diagnosed with COVID - 19 pneumonia between March 11 th , 2020 and April 25th, 2020 in the emergency, internal medicine and cardiology outpatient clinics.
- patients diagnosed by pcr testing and computed tomography of the chest
You may not qualify if:
- patients below 18 years of age
- patients with an alternative aetiology of pneumonia
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Vital Hospital
Bahçelievler, Istanbul, 34230, Turkey (Türkiye)
Related Publications (2)
Wang Q, Ma J, Jiang Z, Ming L. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in acute pulmonary embolism: a systematic review and meta-analysis. Int Angiol. 2018 Feb;37(1):4-11. doi: 10.23736/S0392-9590.17.03848-2. Epub 2017 May 24.
PMID: 28541022BACKGROUNDLippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020 Jun 25;58(7):1131-1134. doi: 10.1515/cclm-2020-0198. No abstract available.
PMID: 32119647BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- M.D.
Study Record Dates
First Submitted
June 5, 2020
First Posted
June 9, 2020
Study Start
June 8, 2020
Primary Completion
July 15, 2020
Study Completion
July 20, 2020
Last Updated
September 23, 2020
Record last verified: 2020-09